Found 16 matching trials
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma PHASE2 The purpose of this study is to test see the combined effects of the study ...
Show More Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma PHASE2 The purpose of this study is to find out whether N10 chemotherapy is a safe...
Show More Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma PHASE2 The purpose of this study is to find out what effect an antibody called Hum...
Show More Status
Active Not Recruiting
Location
Children's Hospital of Los Angeles (Data Collection Only)
Learn More & Join Trial
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma PHASE2 This is an prospective study to evaluate the safety and efficacy of naxitam...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Naxitamab and GM-CSF in People With Neuroblastoma N/A This is an Expanded Access Program (EAP) that will give the participants ac...
Show More Status
No Longer Available
Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow PHASE2 Children and adults diagnosed with high-risk neuroblastoma patients with pr...
Show More Status
Active Not Recruiting
Location
Riley Hospital for Children
Learn More & Join Trial
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 PHASE2 This clinical trial will evaluate the safety of chemoimmunotherapy with Nax...
Show More Location
Shaare Zedek Medical Center
Learn More & Join Trial
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma PHASE1 This research is being done to investigate a treatment regimen of Irinoteca...
Show More Location
Boston Children's Hospital
Learn More & Join Trial
Study of Chemoimmunotherapy for High-Risk Neuroblastoma EARLY_PHASE1 The purpose of this study is to find out whether an experimental drug calle...
Show More Status
Active Not Recruiting
Location
Memorial Sloan Kettering Cancer Center
Learn More & Join Trial
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. PHASE2 This is a single-arm, uncontrolled, international, multi-center, clinical,p...
Show More Location
Hong Kong Children's Hospital
Learn More & Join Trial